Morano Susan E purchased $100K of BSX

Boston Scientific (BSX) shares declined in premarket trading Wednesday despite Q3 2026 earnings beating expectations. The company reduced its full-year outlook, attributing the change to a recent cybersecurity incident. According to the company, the incident impacted its financial performance. BSX reported Q3 2026 financials but did not disclose specific figures in the provided text.

Boston Scientific (BSX) shares fell 3.6% to $43.42 in pre-market trading after reporting Q3 2026 earnings. Adjusted EPS of $0.73 missed estimates by $0.02, while revenue of $5.14B exceeded expectations. The company cut Q4 and full-year 2026 EPS guidance due to a cyberattack and other challenges, citing a 1%-3% expected decline in Q4 sales.

Boston Scientific reported Q3 2026 revenue of $5.14 billion, exceeding estimates by 1.4%, but missed revenue and EPS guidance for Q4 2026. Adjusted EPS was in line at $0.73. Operating margin declined to 16.1% from 20.7% year-over-year, and organic revenue grew 1.5%.

Boston Scientific reported Q3 2026 net sales of $5.14B, up 1.5% YoY, and adjusted EPS of $0.73. The company lowered its full-year 2026 outlook to 4.25% sales growth and adjusted EPS of $3.16-$3.18. Gross profit and operating income declined YoY. The company announced new product clearances and collaborations.

Boston Scientific (BSX) reported Q3 revenue of $5.14B, beating estimates, but EPS missed. Shares fell 3.48% pre-market due to weak Q4 and full-year guidance. The company cited a cybersecurity incident as a challenge. Cardiovascular and MedSurg segments showed modest growth, with mixed international results.

Boston Scientific (BSX) reported Q3 EPS of $0.73, missing estimates by $0.02, but revenue of $5.14B exceeded expectations. The company guided Q4 2026 EPS to $0.77-$0.79, below consensus of $0.83, and FY 2026 EPS to $3.16-$3.18, below consensus of $3.24. The stock is down 3.57% over 3 months and 55.07% over 12 months.